Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug testing

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,069 result(s) found for: Drug testing. Displaying page 6 of 104.
    EudraCT Number: 2015-004024-54 Sponsor Protocol Number: GS-US-380-1489 Start Date*: 2016-02-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretrovira...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004588-30 Sponsor Protocol Number: TED-C13-003 Start Date*: Information not available in EudraCT
    Sponsor Name:NPS Pharmaceuticals, Inc.
    Full Title: A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year through 17 Years, with Short Bowel Syndrome who are Dependent on Parenteral Support
    Medical condition: Short Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10049416 Short-bowel syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005544-10 Sponsor Protocol Number: NIHRCDF Start Date*: 2012-04-10
    Sponsor Name:Imperial College London
    Full Title: Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10052996 Inhalation therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000346-19 Sponsor Protocol Number: HP-CD-CL-2003 Start Date*: 2018-06-04
    Sponsor Name:Herantis Pharma Plc
    Full Title: A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-C...
    Medical condition: Idiopathic Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2012-004178-24 Sponsor Protocol Number: RP-OSV-02-D Start Date*: 2013-12-27
    Sponsor Name:Fresenius Medical Care Deutschland GmbH
    Full Title: Study to investigate the therapeutic equivalence of OsvaRen® tablets and OsvaRen® granules
    Medical condition: Hyperphosphataemia in end stage renal failure patients on extracorporeal renal replacement therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001218-26 Sponsor Protocol Number: TRO19622 CL E Q 1204-1 Start Date*: 2008-06-19
    Sponsor Name:TROPHOS SA
    Full Title: A double blind, placebo controlled study of the effect of 330mg QD of TRO19622 in the treatment of Chemotherapy Induced Peripheral Neuropathy.
    Medical condition: Symptoms of chemotherapy induced peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036109 Polyneuropathy due to drugs LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-005101-29 Sponsor Protocol Number: KCH-MDS-04-1.0 Start Date*: 2005-02-24
    Sponsor Name:King's College Hospital NHS Foundation Trust [...]
    1. King's College Hospital NHS Foundation Trust
    2. King's College London
    Full Title: THE EFFICACY AND SAFETY OF LENALIDOMIDE (Revlimid®) MONOTHERAPY IN RED BLOOD CELL TRANSFUSION DEPENDENT SUBJECTS WITH MYELODYSPLASTIC SYNDROME ASSOCIATED WITH A DEL (5q) CYTOGENETIC ABNORMALITY
    Medical condition: Myelodysplastic Syndrome (MDS) associated with a Del (5q) cytogenetic abnormality
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10067097 5q minus MDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001139-38 Sponsor Protocol Number: 3475-689 Start Date*: 2018-02-02
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for StageIII-IVA Resectable Locoregionally Ad...
    Medical condition: Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) ES (Restarted) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003988-10 Sponsor Protocol Number: GS-US-380-1490 Start Date*: 2016-02-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infec...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001684-21 Sponsor Protocol Number: NV1205-009 Start Date*: 2018-04-20
    Sponsor Name:Neurov Acquisition LLC
    Full Title: Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)
    Medical condition: Childhood Cerebral Adrenoleukodystrophy (CCALD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Prematurely Ended) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-003617-33 Sponsor Protocol Number: 03-2005 Start Date*: Information not available in EudraCT
    Sponsor Name:Charité
    Full Title: A Randomised Cross-Over Study to Explore the Pathophysiological Mechanisms Involved in the Treatment of Actinic Keratoses with Solaraze
    Medical condition: actinic keratosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001331-26 Sponsor Protocol Number: PROLIFIC2020 Start Date*: 2020-04-14
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: ChemoPROphyLaxIs For covId-19 infeCtious disease (the PROLIFIC trial)
    Medical condition: Coronavirus disease 2019 (COVID-19) caused by the infection, SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-005476-32 Sponsor Protocol Number: VR004/008 Start Date*: 2006-02-02
    Sponsor Name:Vectura Group plc
    Full Title: A Phase IIb, Randomised, Double-Blind, Placebo Controlled, Dose Finding Study Assessing the Haemodynamic Safety and "At Home" Efficacy of Inhaled VR004 in patients with Erectile Dysfunction (ED).
    Medical condition: Erectile dysfunction
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005086-20 Sponsor Protocol Number: CHDR1117 Start Date*: 2011-11-22
    Sponsor Name:Centre for Human Drug Research (CHDR)
    Full Title: Effects of paracetamol on nociception in adolescents.
    Medical condition: Nociceptive pain (disorders)
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002520-13 Sponsor Protocol Number: 251602 Start Date*: 2022-07-18
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: Phase IV Multi-center, Prospective, Interventional, Post-marketing Study in Hemophilia B Patients in India receiving RIXUBIS as On-demand or Prophylaxis Under Standard Clinical Practice
    Medical condition: Hemophilia B
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004926-26 Sponsor Protocol Number: PRV-031-001 Start Date*: 2019-11-21
    Sponsor Name:Provention Bio, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, anti-CD3 Monoclonal Antibody, in ...
    Medical condition: Type 1 Diabetes (T1D)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012594 Diabetes LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) DE (Completed) FR (Completed) FI (Ongoing) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-001817-35 Sponsor Protocol Number: 111958 Start Date*: 2021-08-04
    Sponsor Name:Radboud University Medical Center
    Full Title: Suboxone (buprenorphine/naloxone) versus methadone opioid rotation in patients with escalated opioid use and chronic pain: a randomized trial.
    Medical condition: Opioid use disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005410-19 Sponsor Protocol Number: HH-AT-001 Start Date*: 2013-03-11
    Sponsor Name:Jessaziekenhuis Hasselt
    Full Title: Developing a Patient Model of Controlled, Radial Artery Access Site Bleeding for Deciding on Anticoagulation Reversal in Patients Treated by Systemic Anticoagulants.
    Medical condition: With the novel oral anticoagulants, including EDOXABAN-DABIGATRANRIVAROXABAN- APIXABAN, we are entering a new era of anticoagulation for atrial fibrillation (AF) (and deep vein thrombosis). Neve...
    Disease: Version SOC Term Classification Code Term Level
    15.1 10022891 - Investigations 10060319 Anticoagulation drug level therapeutic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003723-29 Sponsor Protocol Number: JBT101-CF-002 Start Date*: 2018-05-11
    Sponsor Name:Corbus Pharmaceuticals, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
    Medical condition: Cystic Fibrosis (CF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) SE (Completed) FR (Completed) PT (Completed) SK (Completed) AT (Completed) BE (Completed) ES (Completed) BG (Completed) NL (Completed) CZ (Completed) GR (Completed) PL (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-002761-63 Sponsor Protocol Number: HPV-301 Start Date*: 2018-04-16
    Sponsor Name:Inovio Pharmaceuticals, Inc.
    Full Title: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H...
    Medical condition: HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) OF THE CERVIX
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022891 - Investigations 10064328 Human papilloma virus test positive PT
    21.1 100000004872 10066237 Cervical high grade squamous intraepithelial lesion LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) FI (Completed) DE (Completed) CZ (Prematurely Ended) ES (Completed) PT (Completed) PL (Completed) SK (Completed) BE (Completed) NL (Ongoing) EE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 19:18:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA